Compass Therapeutics Announces Issuance of Composition of Matter and Method Patents Covering Its Lead Immuno-oncology Candidate, CTX-471

Compass Therapeutics Announces Issuance of Composition of Matter and Method Patents Covering Its Lead Immuno-oncology Candidate, CTX-471

Jun. 17, 2019 by

CAMBRIDGE, Mass., June 17, 2019 — Compass Therapeutics, a clinical-stage biotechnology company targeting the human immune synapse with a new generation of monoclonal and multispecific antibody therapeutics, today announced that

Compass Therapeutics Expands Leadership Team with Appointments of Chief Medical Officer and Chief Financial Officer

Compass Therapeutics Expands Leadership Team with Appointments of Chief Medical Officer and Chief Financial Officer

Dec. 19, 2018 by

CAMBRIDGE, Mass. Dec. 19, 2018 — Compass Therapeutics, a biotechnology company committed to the ambitious goal of comprehensively drugging the human immune system, today announced the appointment of veteran biopharma